Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis

Overview of attention for article published in Neurology and Therapy, January 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 27 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 13,788 followers.

Natalizumab for achieving relapse-free in Japanese #multiplesclerosis patients https://t.co/IxW1v3cVhG

Reply Repost Favourite

Natalizumab for Achieving Relapse-Free, T1 Enhancing-Lesion-Free, & T2 Lesion-Free Status in Japanese #MS Patients https://t.co/CZIDEF10AW

Reply Repost Favourite